J Immunother Cancer
Cell- and Tissue-Based TherapyImmunotherapyInterleukin-2
Dr. Ann Willman Silk, MD
NPI1477717106PAC ID2961623798
- Medicare services, 2024
- 453
- Medicare patients, 2024
- 222
- Part D claims, 2024
- 104
- Publications
- 75
- Clinical trials
- 6
- Practice address
- 450 Brookline Avenue, Boston, MA 02115
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Find Dr. Silk's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Ann Willman Silk is a medical oncologist in Boston, Massachusetts
Dr. Silk practices at Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute.
Dr. Silk's NPI, 1477717106, was assigned on July 11, 2008. Dr. Silk graduated from University of Pittsburgh School of Medicine in 2008. Dr. Silk holds Massachusetts license 277798.
NPI and contact details
- NPI
- 1477717106NPI Registry (opens in a new tab)
- Medicare PAC ID
- 2961623798
- NPI enumeration date
- July 11, 2008
- NPI status
- Active
- Accepts Medicare assignment
- Yes
- Offers telehealth
- Yes
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Female
- Estimated age
- 44
- Medical school graduation
- 2008
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Affiliation Data; and Doctors and Clinicians National Downloadable File (CMS)
Dr. Ann Willman Silk practices at Dana-Farber Cancer Institute in Boston, Massachusetts
Dr. Silk's primary practice is Dana-Farber Cancer Institute, at 450 Brookline Avenue, Boston, MA 02115.
- Dana-Farber Cancer Institute450 Brookline Avenue, Boston, MA 02115
Source: Dmand AI Affiliation Data
Dr. Ann Willman Silk is affiliated with 5 sites of care and 1 medical group
Dr. Silk's primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Dr. Silk is also affiliated with Massachusetts General Hospital. The medical group on file is Binney Medical Group. Dmand AI also links Dr. Silk to 3 more hospitals, each named with a free account.
Sources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data
Dmand AI tracks the EHR system at Dr. Ann Willman Silk's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Silk practices, 5 sites in all. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Dana-Farber Cancer Institute | Available with a free account |
| +4 more affiliated sites | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
See the EHR and IT leaders at every hospital where Dr. Silk practices
Dmand AI maps EHR vendors, IT decision makers and buying committees across Dana-Farber Cancer Institute and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Ann Willman Silk is one of 290 medical oncologists in Massachusetts
Medical oncology is Dr. Silk's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Silk is licensed in Massachusetts.
Specialties and state licenses
- Medical oncology, MassachusettsPrimary
Medical oncologists near Dr. Silk
Counts of medical oncologists with a Dmand AI profile, by place and practice. Each opens the list.
290medical oncologists in Massachusetts228medical oncologists in Boston96medical oncologists at Dana-Farber Cancer Institute
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Ann Willman Silk billed Medicare for 453 services in 2024
CMS data shows 453 Medicare services from Dr. Silk across 4 procedure codes in 2024, for 222 Medicare patients. Medicare paid $51,585 for them.
Medicare services, 2024453
Medicare patients222
Paid by Medicare$51,585
Procedure codes4
Dr. Silk's Medicare services by type, 2023 to 2024
- 2023
- 2024
- Office and hospital visits
- 2023: 5622024: 45319%
Where Dr. Silk's Medicare services took place, 2024
- In an office215%
- In a facility43295%
Dr. Silk compared with the Massachusetts median for medical oncologists, 2024
- Dr. Silk
- Massachusetts median
- Medicare services
- 453vs 26074% above
- Medicare patients
- 222vs 1092.0 times
- Part D claims
- 25vs 6360% below
Medians across 259 medical oncologists in Massachusetts with Dmand AI profiles that report each measure.
Dr. Silk's most billed Medicare procedure codes, 2024
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Silk?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Silk and other medical oncologists in Massachusetts.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Ann Willman Silk treated 222 Medicare patients in 2024, average age 77
CMS counts 222 Medicare patients who saw Dr. Silk in 2024. The largest group is 75 to 84, with 102 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 7% are also on Medicaid. Their average risk score is 2.69, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.
Across all payers, Dmand AI patient panel data puts Dr. Silk's median patient age at 75, with 35% women.
Medicare patients, 2024222
Average age77
Average risk score2.69
Also on Medicaid7%
Dr. Silk's Medicare patients by age, 2024
CMS leaves out age groups with fewer than 11 patients.
Dr. Silk's Medicare patients by sex, 2024
- Women8337%
- Men13963%
Chronic conditions among Dr. Silk's Medicare patients, 2024
- High cholesterol75%
- High blood pressure73%
- Arthritis46%
- Ischemic heart disease36%
- Cancer35%
- Chronic kidney disease32%
- Anxiety28%
- Diabetes27%
Share of Medicare patients with each condition. A patient can have several.
Dr. Silk's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 75
Patient panel by sex, all payers
- Women35%
- Men65%
Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data
Dr. Ann Willman Silk wrote 104 Medicare Part D claims in 2024
In 2024, Dr. Silk wrote 104 Medicare Part D claims for 34 patients. 85% of them were for generic drugs. CMS names the drug for 25 of them, across 1 drug with 11 or more claims each, at $340 in total drug cost. In 2023, CMS named 26 claims across 1 drug.
Part D claims, 2024104
Drugs named by CMS1
Total drug cost$340
Part D patients34
Dr. Silk's Part D claims by kind of drug, 2024
- Generic88 claims85%
- Brand-name16 claims15%
Dr. Silk's most prescribed drugs by claims, 2024
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Part D claims for drugs CMS names, 2023 to 2024
- 2023
- 2024
- Claims for drugs CMS names
- 2023: 262024: 254%
Drugs named by CMS: 1 in 2024, 1 in 2023.
Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data
Dr. Ann Willman Silk scored 84 out of 100 in Medicare's MIPS program for 2024
CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Silk for performance year 2024, reported as part of a group. Dr. Silk accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Silk as offering telehealth.
- Accepts Medicare assignment
- Yes
- Offers telehealth
- Yes
Dr. Silk's MIPS scores, performance year 2024
- 84of 100Final score
- 65of 100Quality
- 100of 100Promoting Interoperability
- 40of 100Improvement Activities
- 69of 100Cost
Each score is out of 100. The final score weighs the categories CMS scored for this clinician.
Sources: Doctors and Clinicians National Downloadable File (CMS); and Clinician Public Reporting: Overall MIPS Performance (CMS), 2024 data, released September 10, 2026
For MedTech and pharma teams
Find medical oncologists like Dr. Silk by procedure volume and prescribing
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Ann Willman Silk has 75 publications on record
Dmand AI links 75 papers to Dr. Silk, published from 2010 to 2025. 2024 was the busiest year, with 14. The most frequent topics are Skin Neoplasms, Immunotherapy and Melanoma. Dr. Silk has published most often in J Immunother Cancer. Dr. Silk's most frequent co-authors are Howard L. Kaufman, MD, Janice M. Mehnert and Manisha Thakuria, MD.
Papers75
Years published2010 to 2025
Dr. Silk's papers by year, 2016 to 2025
Topics Dr. Silk writes about most
- Skin Neoplasms
- Immunotherapy
- Melanoma
- Carcinoma, Merkel Cell
- Carcinoma, Squamous Cell
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
- Biomarkers, Tumor
Dr. Silk's most frequent co-authors
- Howard L. Kaufman, MD15 shared papers
- Janice M. Mehnert15 shared papers
- Manisha Thakuria, MD13 shared papers
Recent publications by Dr. Silk
J Immunother Cancer
Drug DevelopmentImmunotherapy
See who Dr. Silk researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Silk works with, so you can find a warm path to the right medical oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Ann Willman Silk has worked on 6 clinical trials
Dmand AI links Dr. Silk to 6 clinical trials, 4 of them phase 1 studies. 2 are still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Carcinoma, Basosquamous. National Cancer Institute (NCI) sponsors the most, 2. Open Payments lists research payments to Dr. Silk that name 3 trials.
Clinical trials with Dr. Silk by phase
- 4Phase 1: 4 trials
- 2Phase 2: 2 trials
- NonePhase 3: no trials
- NonePhase 4: no trials
Conditions in Dr. Silk's trials
- Melanoma
- Nevi and Melanomas
- Carcinoma, Basosquamous
- Carcinoma, Merkel Cell
- Penile Neoplasms
Investigators on the most trials with Dr. Silk
- George Ansstas, MD1 shared trial
- Sunandana Chandra, MD1 shared trial
- Frances A. Collichio, MD1 shared trial
Recent clinical trials with Dr. Silk
A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors (opens in a new tab)
Active, not recruitingPhase 1
Penile NeoplasmsUreteral NeoplasmsIpilimumabNivolumabCabozantinib S-malate
Phase 1 Trial of Intralesional Immunotherapy With IFx-Hu2.0 Vaccine in Patients With Advanced Non-melanoma Skin Cancers (opens in a new tab)
CompletedPhase 1
Carcinoma, Merkel CellPolyomavirus InfectionsIFx-Hu2.0
MelanomaNevi and MelanomasIpilimumabNivolumabTroriluzole
A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking Antibodies (opens in a new tab)
CompletedPhase 1
Urinary Bladder NeoplasmsCarcinoma, Renal CellEnzyme Inhibitor TherapyNivolumabPembrolizumab
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (opens in a new tab)
Active, not recruitingPhase 2
Carcinoma, BasosquamousEccrine PorocarcinomaNivolumabTalimogene Laherparepvec
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Ann Willman Silk received $112,591 in industry payments from 2016 to 2025
CMS Open Payments shows 137 general payments to Dr. Silk from 12 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 80% of the total. Merck Sharp & Dohme Corporation paid the most, $42,645. It also lists 11 research payments totaling $2,908 from 2024 to 2025, naming 3 clinical trials.
General payments to Dr. Silk by program year, 2016 to 2025
General payments to Dr. Silk by kind, 2016 to 2025
$112.6Kin total
- Consulting fees$90,34480%
- Travel and lodging$14,87113%
- Food and beverage$4,9674%
- Honoraria$2,4002%
- Education$100%
Companies that paid Dr. Silk the most, 2016 to 2025
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Dr. Ann Willman Silk graduated from University of Pittsburgh School of Medicine
Dr. Silk graduated from University of Pittsburgh School of Medicine in 2008.
- Medical school
Source: Dmand AI Professional Profile Data
Sources for Dr. Ann Willman Silk's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | Dmand AI Affiliation Data |
| Primary practice, affiliations and health system | Dmand AI Affiliation DataDmand AI Org Hierarchy Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab) |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab) |
| MIPS scores, telehealth, assignment and procedure percentiles | Doctors and Clinicians National Downloadable File (CMS) (opens in a new tab)Clinician Public Reporting: Overall MIPS Performance (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| Training, board certification and memberships | Dmand AI Professional Profile Data |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Ann Willman Silk
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Ann Willman Silk's NPI number?
Dr. Ann Willman Silk's NPI number is 1477717106. It was assigned on July 11, 2008, and it is active in the NPI Registry.
What kind of doctor is Dr. Ann Willman Silk?
Dr. Ann Willman Silk is a medical oncologist in Boston, Massachusetts. The primary specialty in the NPI Registry is Medical Oncology Physician (taxonomy code 207RX0202X).
Where does Dr. Ann Willman Silk practice?
Dr. Silk practices at 450 Brookline Avenue, Boston, MA 02115. Dr. Silk's primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Dmand AI also links Dr. Silk to 3 hospitals.
What is Dr. Ann Willman Silk's medical license number?
Dr. Silk holds Massachusetts license 277798.
Which hospitals is Dr. Ann Willman Silk affiliated with?
Dr. Silk practices at Dana-Farber Cancer Institute in Boston, Massachusetts. Dr. Silk is also affiliated with Massachusetts General Hospital. Dmand AI links Dr. Silk to 3 more hospitals.
What medical group is Dr. Ann Willman Silk part of?
Dr. Silk is linked to Binney Medical Group.
Does Dr. Ann Willman Silk accept Medicare?
Yes. CMS data shows Dr. Silk billed Medicare for 453 services in 2024, and Dr. Silk accepts Medicare assignment.
Does Dr. Ann Willman Silk offer telehealth?
Yes. The CMS Doctors and Clinicians file lists Dr. Silk as offering telehealth services.
What is Dr. Ann Willman Silk's MIPS score?
Dr. Silk's MIPS final score for performance year 2024 is 84 out of 100, reported as part of a group.
How many Medicare patients does Dr. Ann Willman Silk see?
CMS counts 222 Medicare patients who saw Dr. Silk in 2024, with an average age of 77.
Show 7 more questionsShow fewer questions
What services does Dr. Ann Willman Silk bill to Medicare?
In 2024, Dr. Silk's most billed Medicare services were office visit, established patient (99215), hospital inpatient care (99233) and office visit, new patient (99205).
Where did Dr. Ann Willman Silk go to medical school?
Dr. Silk graduated from University of Pittsburgh School of Medicine in 2008.
What drugs does Dr. Ann Willman Silk prescribe most?
In 2024 Medicare Part D data, Dr. Silk's most prescribed drugs by claims were Levothyroxine Sodium.
Has Dr. Ann Willman Silk received payments from drug or device companies?
CMS Open Payments shows $112,591 in general payments to Dr. Silk from 12 companies from 2016 to 2025. The largest total came from Merck Sharp & Dohme Corporation.
How long has Dr. Ann Willman Silk been practicing?
Dr. Silk graduated from medical school in 2008, 18 years ago.
Does Dr. Ann Willman Silk do research?
Dmand AI links 75 publications to Dr. Silk, published from 2010 to 2025. Dr. Silk has worked on 6 clinical trials.
Who does Dr. Ann Willman Silk publish with?
Dr. Silk's most frequent co-authors are Howard L. Kaufman, MD (15 shared papers), Janice M. Mehnert (15 shared papers) and Manisha Thakuria, MD (13 shared papers).
Selling to medical oncology practices?
See medical oncologists in Massachusetts by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card